内界膜剥除联合曲安奈德治疗玻璃体黄斑牵拉综合征  

The treatment of vitreomacular traction syndrome by removing inner limiting membranne and injecting TA into vitreous space

作　　者：高雪霞[1] 范志华[1] 王瑞峰[1] 

机构地区：[1]郑州市第二人民医院眼科,河南省郑州市450006

出　　处：《中国实用眼科杂志》2016年第7期720-722,共3页Chinese Journal of Practical Ophthalmology

摘　　要：目的观察内界膜剥除联合曲安奈德注射治疗玻璃体黄斑牵拉综合征（VTS）的临床疗效。方法对2013年8月至2015年3月在郑州市第二人民医院眼科，收治的玻璃体黄斑牵拉综合征患者58例（58只眼），观察患者术前及术后的视力及视网膜厚度（CMT）变化。结果术后两周、1月、3月，患者BCVA逐渐提高，与术前比较差异有统计学意义（P〈0．05）。术后两周、1月、3月，CMT逐渐减少，与术前比较差异有统计学意义（P〈0．05）。结论内界膜剥除联合曲安奈德注射治疗玻璃体黄斑牵拉综合征是安全有效的，可以减轻黄斑水肿，提高视力，且术后避免黄斑前膜的形成。Objective To observe the effect to vitreomacular traction syndrome by means of removing inner limiting membrane and injecting TA into vitreous space. Methods Fifty-eight eyes with VTS from August 2013 to March 2015 were retrospectively reviewed. The change of the vision and the thickness of macular before and after operation （2 weeks, 1 month and 3 months） were observed. Results The vision promoted gradually in 2 weeks, 1 month and 3 months after operation, the difference was significant, P 〈0.05. The thickness of macular decreased obviously, the difference was significant, P 〈0.05. Conclusions Removing inner limiting membrane and injecting TA into vitreous space to treat VTS is safe and effective, alleviating macular edema, improving vision, avoiding epi-macular membrane.

关 键 词：玻璃体黄斑牵拉综合征 视网膜内界膜剥除 玻璃体腔注射 

分 类 号：R774.5[医药卫生—眼科]